Abstract
Cardiovascular diseases are the leading cause of death in industrialized nations worldwide. Of all deaths resulting from cardiovascular diseases, 2% are caused by inflammatory heart disease; specifically, myocarditis. The etiology causing myocarditis still remains unclear. Both infectious and non-infectious factors are capable of triggering myocarditis. Acute myocarditis manifests itself in a variety of ways ranging from subclinical disease to sudden heart failure, as well as the occurrence of chest pain, palpitations, and syncope. Myocarditis can lead to dilated cardiomyopathy, this being the most frequent cause for heart transplantation. Since the underlying mechanism and the pathways behind the disease initiation and progression still need to be elucidated, the need for mouse models simulating the human disease is evident. Various mouse models are frequently used to study myocarditis. Inflammation of the myocardium as a result of infectious agents can be investigated with a widely used animal model where mice are infected with coxsackievirus B3. For autoimmune (non-viral) myocarditis, several mouse models (including induction with myosin or troponin I) have been established to better understand the role of autoantibodies and their influence on disease progression. With these different models, various phases of the disease can be investigated and these findings are used to develop more specific therapies that can be translated into the clinic as a "bench-to-bedside" approach.
Keywords: Animal models, myocarditis, autoimmunity, coxsackievirus B3, myosin, troponin I, DCM.
Current Pharmaceutical Design
Title:Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Volume: 21 Issue: 18
Author(s): Anna-Maria Muller, Andrea Fischer, Hugo A. Katus and Ziya Kaya
Affiliation:
Keywords: Animal models, myocarditis, autoimmunity, coxsackievirus B3, myosin, troponin I, DCM.
Abstract: Cardiovascular diseases are the leading cause of death in industrialized nations worldwide. Of all deaths resulting from cardiovascular diseases, 2% are caused by inflammatory heart disease; specifically, myocarditis. The etiology causing myocarditis still remains unclear. Both infectious and non-infectious factors are capable of triggering myocarditis. Acute myocarditis manifests itself in a variety of ways ranging from subclinical disease to sudden heart failure, as well as the occurrence of chest pain, palpitations, and syncope. Myocarditis can lead to dilated cardiomyopathy, this being the most frequent cause for heart transplantation. Since the underlying mechanism and the pathways behind the disease initiation and progression still need to be elucidated, the need for mouse models simulating the human disease is evident. Various mouse models are frequently used to study myocarditis. Inflammation of the myocardium as a result of infectious agents can be investigated with a widely used animal model where mice are infected with coxsackievirus B3. For autoimmune (non-viral) myocarditis, several mouse models (including induction with myosin or troponin I) have been established to better understand the role of autoantibodies and their influence on disease progression. With these different models, various phases of the disease can be investigated and these findings are used to develop more specific therapies that can be translated into the clinic as a "bench-to-bedside" approach.
Export Options
About this article
Cite this article as:
Muller Anna-Maria, Fischer Andrea, Katus A. Hugo and Kaya Ziya, Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis, Current Pharmaceutical Design 2015; 21 (18) . https://dx.doi.org/10.2174/1381612821666150316123711
DOI https://dx.doi.org/10.2174/1381612821666150316123711 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews Effects of Verbascoside Administration on the Blood Parameters and Oxidative Status in Jennies and Their Suckling Foals: Potential Improvement of Milk for Human Use
Endocrine, Metabolic & Immune Disorders - Drug Targets Aging is Not a Disorder
Current Aging Science Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets Microbial Metabolomics
Current Genomics HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions
Current Diabetes Reviews Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Role of Ca2+-Sensitive K+ Currents in Controlling Ventricular Repolarization: Possible Implications for Future Antiarrhytmic Drug Therapy
Current Medicinal Chemistry Reduction of Sodium Intake is a Prerequisite for Preventing and Curing High Blood Pressure in Hypertensive Patients - Second Part: Guidelines
Current Hypertension Reviews Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Dihydrobenzo[1,4]oxathiine: A Multi-Potent Pharmacophoric Heterocyclic Nucleus
Current Medicinal Chemistry Cardiac Sarcolemmal Ion Channels and Transporters as Possible Targets for Antiarrhythmic and Positive Inotropic Drugs: Strategies of the Past-Perspectives of the Future
Current Pharmaceutical Design Lipids in the Diet and the Fatty Acid Profile in Beef: A Review and Recent Patents on the Topic
Recent Patents on Food, Nutrition & Agriculture High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Alzheimer’s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome
Current Neuropharmacology Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science MRI Contrast Agents: Current Status and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry